BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KRAS-specific Autologous TCR-T cell readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of KRAS-specific Autologous TCR-T cell\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06767046-2584@assetmemo.bio
DTSTAMP:20261121T011044Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:KRAS-specific Autologous TCR-T cell: Phase 1 readout est. (NCT06767
 046)
DESCRIPTION:KRAS-specific Autologous TCR-T cell\, phase 1\, Non-Small Cell 
 Lung Cancer.\nStudy: KRAS-Specific Autologous TCR-T Cell Therapy for KRAS 
 Mutation in Advanced Solid Tumors\nEstimated primary completion: 30 Novemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/kras-specifi
 c-autologous-tcr-t-cell#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06767046
URL:https://assetmemo.bio/drug/kras-specific-autologous-tcr-t-cell#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
